

# **Epilepsy Drugs Market Size, Share & Trends Analysis Report By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030**

<https://marketpublishers.com/r/E217541042A7EN.html>

Date: February 2025

Pages: 90

Price: US\$ 5,950.00 (Single User License)

ID: E217541042A7EN

## **Abstracts**

**This report can be delivered to the clients within 3 Business Days**

### **Epilepsy Drugs Market Growth & Trends**

The global epilepsy drugs market size is estimated to reach USD 15.47 billion by 2030, expanding at a CAGR of 5.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness training to the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

### **Epilepsy Drugs Market Report Highlights**

Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel

(Fycompa).

The third generation anti-epileptics segment accounted for the largest revenue share of around 39.7% in 2024. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.

North America dominated the market with the largest revenue share of around 38.7% in 2024. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.

Asia Pacific epilepsy drugs market is expected to register at a notable CAGR over the forecast period, attributed to the large and diverse population of the region, surging prevalence of epilepsy, and improving healthcare infrastructure.

## Contents

### CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
  - 1.2.1. Treatment
  - 1.2.2. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
  - 1.5.1. Purchased Database
  - 1.5.2. GVR's Internal Database
  - 1.5.3. Secondary Sources
  - 1.5.4. Primary Research
- 1.6. Information Analysis
  - 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
  - 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives

### CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

### CHAPTER 3. EPILEPSY DRUGS MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
  - 3.2.1. Market Driver Analysis
  - 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
  - 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    - 3.3.1.1. Supplier power
    - 3.3.1.2. Buyer power

- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTLE Analysis

## **CHAPTER 4. EPILEPSY DRUGS MARKET: TREATMENT BUSINESS ANALYSIS**

- 4.1. Treatment Market Share, 2024 & 2030
- 4.2. Treatment Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, By Treatment, 2018 to 2030 (USD Million)
- 4.4. First Generation Anti-epileptics
  - 4.4.1. First Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
- 4.5. Second Generation Anti-epileptics
  - 4.5.1. Second Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
- 4.6. Third Generation Anti-epileptics
  - 4.6.1. Third Generation Anti-epileptics Market, 2018 - 2030 (USD Million)

## **CHAPTER 5. EPILEPSY DRUGS MARKET: DISTRIBUTION CHANNEL BUSINESS ANALYSIS**

- 5.1. Distribution Channel Market Share, 2024 & 2030
- 5.2. Distribution Channel Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, By Distribution Channel, 2018 to 2030 (USD Million)
- 5.4. Hospital Pharmacies
  - 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
- 5.5. Retail Pharmacies
  - 5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
- 5.6. Others
  - 5.6.1. Others Market, 2018 - 2030 (USD Million)

## **CHAPTER 6. EPILEPSY DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS**

- 6.1. Regional Market Share Analysis, 2024 & 2030
- 6.2. Regional Market Dashboard
- 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 6.4. North America

#### 6.4.1. North America Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

##### 6.4.2. U.S.

###### 6.4.2.1. Key Country Dynamics

###### 6.4.2.2. Regulatory Framework

###### 6.4.2.3. Competitive Insights

#### 6.4.2.4. U.S. Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

##### 6.4.3. Canada

###### 6.4.3.1. Key Country Dynamics

###### 6.4.3.2. Regulatory Framework

###### 6.4.3.3. Competitive Insights

#### 6.4.3.4. Canada Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

##### 6.4.4. Mexico

###### 6.4.4.1. Key Country Dynamics

###### 6.4.4.2. Regulatory Framework

###### 6.4.4.3. Competitive Insights

#### 6.4.4.4. Mexico Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

#### 6.5. Europe

##### 6.5.1. Europe Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

##### 6.5.2. U.K.

###### 6.5.2.1. Key Country Dynamics

###### 6.5.2.2. Regulatory Framework

###### 6.5.2.3. Competitive Insights

#### 6.5.2.4. U.K. Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

##### 6.5.3. Germany

###### 6.5.3.1. Key Country Dynamics

###### 6.5.3.2. Regulatory Framework

###### 6.5.3.3. Competitive Insights

#### 6.5.3.4. Germany Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

##### 6.5.4. France

###### 6.5.4.1. Key Country Dynamics

###### 6.5.4.2. Regulatory Framework

###### 6.5.4.3. Competitive Insights

6.5.4.4. France Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.5. Italy

6.5.5.1. Key Country Dynamics

6.5.5.2. Regulatory Framework

6.5.5.3. Competitive Insights

6.5.5.4. Italy Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.6. Spain

6.5.6.1. Key Country Dynamics

6.5.6.2. Regulatory Framework

6.5.6.3. Competitive Insights

6.5.6.4. Spain Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.7. Denmark

6.5.7.1. Key Country Dynamics

6.5.7.2. Regulatory Framework

6.5.7.3. Competitive Insights

6.5.7.4. Denmark Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.8. Norway

6.5.8.1. Key Country Dynamics

6.5.8.2. Regulatory Framework

6.5.8.3. Competitive Insights

6.5.8.4. Norway Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.9. Sweden

6.5.9.1. Key Country Dynamics

6.5.9.2. Regulatory Framework

6.5.9.3. Competitive Insights

6.5.9.4. Sweden Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6. Asia Pacific

6.6.1. Asia Pacific Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.2. Japan

6.6.2.1. Key Country Dynamics

6.6.2.2. Regulatory Framework

6.6.2.3. Competitive Insights

6.6.2.4. Japan Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.3. China

6.6.3.1. Key Country Dynamics

6.6.3.2. Regulatory Framework

6.6.3.3. Competitive Insights

6.6.3.4. China Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.4. India

6.6.4.1. Key Country Dynamics

6.6.4.2. Regulatory Framework

6.6.4.3. Competitive Insights

6.6.4.4. India Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.5. South Korea

6.6.5.1. Key Country Dynamics

6.6.5.2. Regulatory Framework

6.6.5.3. Competitive Insights

6.6.5.4. South Korea Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.6. Australia

6.6.6.1. Key Country Dynamics

6.6.6.2. Regulatory Framework

6.6.6.3. Competitive Insights

6.6.6.4. Australia Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.7. Thailand

6.6.7.1. Key Country Dynamics

6.6.7.2. Regulatory Framework

6.6.7.3. Competitive Insights

6.6.7.4. Thailand Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.7. Latin America

6.7.1. Latin America Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.7.2. Brazil

6.7.2.1. Key Country Dynamics

6.7.2.2. Regulatory Framework

6.7.2.3. Competitive Insights

6.7.2.4. Brazil Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.7.3. Argentina

6.7.3.1. Key Country Dynamics

6.7.3.2. Regulatory Framework

6.7.3.3. Competitive Insights

6.7.3.4. Argentina Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.8. Middle East and Africa

6.8.1. Middle East and Africa Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.8.2. South Africa

6.8.2.1. Key Country Dynamics

6.8.2.2. Regulatory Framework

6.8.2.3. Competitive Insights

6.8.2.4. South Africa Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.8.3. Saudi Arabia

6.8.3.1. Key Country Dynamics

6.8.3.2. Regulatory Framework

6.8.3.3. Competitive Insights

6.8.3.4. Saudi Arabia Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.8.4. UAE

6.8.4.1. Key Country Dynamics

6.8.4.2. Regulatory Framework

6.8.4.3. Competitive Insights

6.8.4.4. UAE Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.8.5. Kuwait

6.8.5.1. Key Country Dynamics

6.8.5.2. Regulatory Framework

6.8.5.3. Competitive Insights

6.8.5.4. Kuwait Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

## **CHAPTER 7. COMPETITIVE LANDSCAPE**

### **7.1. Participant Overview**



## 7.2. Company Market Position Analysis

## 7.3. Company Categorization

## 7.4. Strategy Mapping

## 7.5. Company Profiles/Listing

### 7.5.1. UCB S.A.

#### 7.5.1.1. Participant's Overview

#### 7.5.1.2. Financial Performance

#### 7.5.1.3. Product Benchmarking

#### 7.5.1.4. Strategic Initiatives

### 7.5.2. Sanofi

#### 7.5.2.1. Participant's Overview

#### 7.5.2.2. Financial Performance

#### 7.5.2.3. Product Benchmarking

#### 7.5.2.4. Strategic Initiatives

### 7.5.3. Pfizer, Inc.

#### 7.5.3.1. Participant's Overview

#### 7.5.3.2. Financial Performance

#### 7.5.3.3. Product Benchmarking

#### 7.5.3.4. Strategic Initiatives

### 7.5.4. Otsuka America Pharmaceutical, Inc.

#### 7.5.4.1. Participant's overview

#### 7.5.4.2. Financial Performance

#### 7.5.4.3. Product Benchmarking

#### 7.5.4.4. Strategic Initiatives

### 7.5.5. Eisai Co., Ltd.

#### 7.5.5.1. Participant's Overview

#### 7.5.5.2. Financial Performance

#### 7.5.5.3. Product Benchmarking

#### 7.5.5.4. Strategic Initiatives

### 7.5.6. Abbott Laboratories, Inc.

#### 7.5.6.1. Participant's Overview

#### 7.5.6.2. Financial Performance

#### 7.5.6.3. Product Benchmarking

#### 7.5.6.4. Strategic Initiatives

### 7.5.7. Novartis AG

#### 7.5.7.1. Participant's Overview

#### 7.5.7.2. Financial Performance

#### 7.5.7.3. Product Benchmarking

#### 7.5.7.4. Strategic Initiatives

- 7.5.8. GlaxoSmithKline plc
  - 7.5.8.1. Participant's Overview
  - 7.5.8.2. Financial Performance
  - 7.5.8.3. Product Benchmarking
  - 7.5.8.4. Strategic Initiatives
- 7.5.9. Sunovion Pharmaceuticals, Inc.
  - 7.5.9.1. Participant's Overview
  - 7.5.9.2. Financial Performance
  - 7.5.9.3. Product Benchmarking
  - 7.5.9.4. Strategic Initiatives
- 7.5.10. Jazz Pharmaceuticals plc
  - 7.5.10.1. Participant's Overview
  - 7.5.10.2. Financial Performance
  - 7.5.10.3. Product Benchmarking
  - 7.5.10.4. Strategic Initiatives
- 7.5.11. Neurelis, Inc.
  - 7.5.11.1. Participant's Overview
  - 7.5.11.2. Financial Performance
  - 7.5.11.3. Product Benchmarking
  - 7.5.11.4. Strategic Initiatives

## I would like to order

Product name: Epilepsy Drugs Market Size, Share & Trends Analysis Report By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/E217541042A7EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E217541042A7EN.html>